Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Share-based Compensation (2017 - 2020)

Historic Share-based Compensation for Monopar Therapeutics (MNPR) over the last 4 years, with Q3 2020 value amounting to $283713.0.

  • Monopar Therapeutics' Share-based Compensation rose 1677.55% to $283713.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $1.3 million, marking a year-over-year increase of 3091.06%. This contributed to the annual value of $4.6 million for FY2024, which is 13986.41% up from last year.
  • Latest data reveals that Monopar Therapeutics reported Share-based Compensation of $283713.0 as of Q3 2020, which was up 1677.55% from $367358.0 recorded in Q2 2020.
  • Monopar Therapeutics' 5-year Share-based Compensation high stood at $367358.0 for Q2 2020, and its period low was $43926.0 during Q3 2017.
  • Its 4-year average for Share-based Compensation is $202519.6, with a median of $233384.0 in 2018.
  • Data for Monopar Therapeutics' Share-based Compensation shows a peak YoY increase of 26872.24% (in 2018) and a maximum YoY decrease of 5528.8% (in 2018) over the last 5 years.
  • Quarter analysis of 4 years shows Monopar Therapeutics' Share-based Compensation stood at $63189.0 in 2017, then soared by 268.72% to $232992.0 in 2018, then rose by 18.8% to $276805.0 in 2019, then rose by 2.5% to $283713.0 in 2020.
  • Its Share-based Compensation was $283713.0 in Q3 2020, compared to $367358.0 in Q2 2020 and $338497.0 in Q1 2020.